06th week of 2011 patent applcation highlights part 43 |
Patent application number | Title | Published |
20110034322 | METHOD FOR PRODUCING A FRACTURE-RESISTANT CATALYST FOR DESULPHURIZING GASES - A method for producing a catalytically active absorber for desulphurizing hydrocarbon streams by mixing a thermally decomposable copper source, a thermally decomposable molybdenum source, zinc oxide, and water, heating the mixture to decompose the copper and molybdenum sources to produce zinc oxide loaded with copper and molybdenum, and calcining the zinc oxide, wherein the zinc oxide has a specific surface area of more than 20 m | 2011-02-10 |
20110034323 | Solid catalyst component for olefin polymerization - A solid catalyst component for olefin polymerization, comprising titanium atoms, magnesium atoms, halogen atoms and hydrocarbyloxy groups, wherein the following filtrate contains titanium atoms in a concentration of 0.08 mg-Ti/ml-filtrate or lower, measured according to a method comprising the steps of (1) preparing a suspension of the solid catalyst component for olefin polymerization in heptane having a concentration of 0.1 g-solid catalyst component/ml-suspension, (2) heating the suspension at 70° C. for 30 minutes under stirring, (3) filtering the suspension, thereby obtaining a filtrate, and (4) measuring a concentration of titanium atoms contained in the filtrate; and a production process of the solid catalyst component. | 2011-02-10 |
20110034324 | Methods for Preparing Catalyst Systems - A process to prepare a catalyst composition that includes combining catalyst precursors in a recycled organic reaction solvent; allowing the catalyst precursors to react to form a catalyst compound; and separating the formed catalyst compound from the reaction solvent is disclosed. | 2011-02-10 |
20110034325 | HIGH PERFORMANCE ORR (OXYGEN REDUCTION REACTION) PGM (PT GROUP METAL) FREE CATALYST - Herein are disclosed PGM-free catalysts, made starting from transition metal phthalocyanine complexes, useful for catalytic ORR, and more particularly, alcohol tolerant catalysts as cathode material for ORR in alkaline and acid medium, characterized by low hydrogen peroxide generation and having better performance, stability and activity. | 2011-02-10 |
20110034326 | COATED CATALYSTS COMPRISING A MULTIMETAL OXIDE COMPRISING MOLYBDENUM - The invention relates to a coated catalyst comprising
| 2011-02-10 |
20110034327 | PROCESS FOR PREPARING CATALYSTS - A process for manufacturing a catalyst composition comprises the steps of (i) precipitating one or more metal compounds from solution using an alkaline precipitant, preferably comprising an alkaline carbonate, optionally in the presence of a thermostabilising material, ii) ageing the precipitated composition, and (iii) recovering and drying the aged composition, wherein the ageing step is performed using a pulse-flow reactor. | 2011-02-10 |
20110034328 | Double Metal-Carbon Nanotube Hybrid Catalyst and Method for Preparation Thereof - Disclosed are a double metal-carbon nanotube hybrid catalyst comprising at least two of transition metals selected from a group consisting of Mn, Fe, Co, Ni, Cu, Mo, Tc, Ru, Rh, Pd, Ag, Re, Os, Ir and Pt which are distributed in the catalyst. The double metal-carbon nanotube hybrid catalyst contains at least two different transition metals with high catalytic activity and may generate hydrogen from an aqueous ammonia-borane (NH | 2011-02-10 |
20110034329 | METHOD FOR FORMING POROUS MATERIAL IN MICROCAVITY OR MICROPASSAGE BY MECHANICOCHEMICAL POLISHING - A surface of a substrate comprising microcavities leading out of the substrate is placed in contact with an aqueous solution comprising a plurality of suspended particles and a fabric. Perpendicular pressure is applied the expanse of the substrate between the fabric and the surface of the substrate, and relative movement of the fabric and the surface is applied to the expanse of the substrate. At least one particle is thus fed into each microcavity, therein forming a porous material that is a catalyst material for nanothread or nanotube growth. | 2011-02-10 |
20110034330 | COATED CATALYSTS COMPRISING A MULTIMETAL OXIDE COMPRISING MOLYBDENUM, BISMUTH AND IRON - The invention relates to a coated catalyst, which is obtainable from a catalyst precursor comprising | 2011-02-10 |
20110034331 | EXHAUST GAS PURIFYING CATALYST AND PRODUCTION METHOD THEREOF - An exhaust gas purifying catalyst including: a plurality of first compounds | 2011-02-10 |
20110034332 | Herbicidal compositions containing N-phosphonomethyl glycine and an auxin herbicide - Herbicidal compositions are provided which cause rapid symptomology while delivering long term control of regrowth of plants. The herbicidal concentrate compositions comprise N-phosphonomethylglycine or a herbicidal derivative thereof, an auxin herbicide or a herbicidal derivative thereof, and at least one surfactant. Also provided is a method for killing or controlling the growth of certain plants by contacting the foliage of the plants with the diluted concentrate composition. | 2011-02-10 |
20110034333 | Method for yield improvement in glyphosate-resistent legumes - Method for increasing the yield in glyphosate-resistant legumes, which comprises treating the plants or the seed with a mixture comprising
| 2011-02-10 |
20110034334 | HERBICIDAL COMPOUNDS - The present invention relates to a method of controlling plants or inhibiting plant growth which comprises applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula (I): wherein A | 2011-02-10 |
20110034335 | Treatment of Ornamental Plants - In a first aspect of the present invention, there is provided a method of treating ornamental plants comprising contacting said plants with a liquid composition comprising of one or more cyclopropene compound, wherein the concentration of the total of all of said one or more cyclopropene compound is 0.3 to 300 milligrams of cyclopropene compound per liter of said liquid composition. | 2011-02-10 |
20110034336 | CRITICAL CURRENT DENSITY ENHANCEMENT VIA INCORPORATION OF NANOSCALE Ba2(Y,RE)NbO6 IN REBCO FILMS - A superconducting article includes a substrate having a biaxially textured surface, and an epitaxial biaxially textured superconducting film supported by the substrate. The epitaxial superconducting film includes particles of Ba | 2011-02-10 |
20110034337 | SUPERCONDUCTIVE CURRENT LIMITER WITH MAGNETIC FIELD TRIGGERING - A superconductive current limiter component with magnetic field triggering has a tubular superconductor element ( | 2011-02-10 |
20110034338 | CRITICAL CURRENT DENSITY ENHANCEMENT VIA INCORPORATION OF NANOSCALE Ba2(Y,RE)TaO6 IN REBCO FILMS - A superconducting article includes a substrate having a biaxially textured surface, and an epitaxial biaxially textured superconducting film supported by the substrate. The epitaxial superconducting film includes particles of Ba | 2011-02-10 |
20110034339 | VERTICALLY-ALIGNED NANOPILLAR ARRAY ON FLEXIBLE, BIAXIALLY-TEXTURED SUBSTRATES FOR NANOELECTRONICS AND ENERGY CONVERSION APPLICATIONS - An article having a biaxially textured substrate surface and a plurality of vertically-aligned, epitaxial nanopillars supported on the surface substrate is disclosed. The article can include a matrix phase deposited on the biaxially textured surface and between the plurality of vertically-aligned, epitaxial nanopillars. The nanopillars can include a coating. The matrix phase and the vertically-aligned, epitaxial nanopillars can form an electronically active layer selected from the group consisting of a superconducting material, a ferroelectric material, a multiferroic material, a magnetic material, a photovoltaic material, a electrical storage material, and a semiconductor material. A method of making the article is also disclosed. | 2011-02-10 |
20110034340 | Systems and Methods for Immunosorbent Assays for Single and Multiple Analytes - The present invention discloses systems and methods for minimizing or eliminating steps in immunosorbent assays for single and multiple analytes by eliminating both the need to attach target molecules to the test well and the need to remove unbound antibodies through rinsing. The immunosorbent assay (ISA) is utilized for a single analyte or target and includes the step of mixing the immunologic molecules with the sample and detection. The present invention further discloses an immunosorbent assay for multiple analytes (ISAMA) for testing a plurality of analytes or targets in a single well using a modified ISA test wherein different tags are attached to different antibody pairs. Alternate embodiments use multiple types of scavenger antigens with corresponding elimination of the need for scavenger antibodies. The present invention discloses various types of test wells for the rapid and simultaneous testing of fluids for a plurality of components and a methodology for a continuous immunosorbent assay. Also disclosed is a method for immunosorbent assay of micro-organisms to determine serotype. | 2011-02-10 |
20110034341 | METHOD AND DEVICE FOR DETERMINING THE RELEVANCE OF SAMPLE ARRAY PREPARATIONS - The invention relates to a method and a device ( | 2011-02-10 |
20110034342 | METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS - The disclosure relates to a method of generating a diverse set of variants to screen improved and novel properties within the variant population, a system for creating the diverse set of variants, and the variant peptides. | 2011-02-10 |
20110034343 | METHOD AND APPARATUS FOR DETECTING ELUTION OF SAMPLES - The invention relates to a method and apparatus for detecting elution of a sample from a sample substrate to incubation buffer contained in a sample well while the sample substrate is still within the well. The method comprises measuring light absorption of the contents of the sample well at a predefined wavelength or wavelength range, and determining, based on the absorption measurement, the degree of elution of the sample. According to the invention, a wavelength or wavelength range is used which is absorbed by at least one elutable component of the sample but transmitted by the sample substrate. The invention provides a reliable way of determining the degree of elution of blood samples in neonatal screening, for example. | 2011-02-10 |
20110034344 | RESPONSE GENE TO COMPLEMENT 32 (RGC-32) IN DISEASE - The invention relates to antibodies that bind to a fragment of the Response Gene to Complement-32 (RGC-32), as well as methods of using these antibodies. Particular methods of using the antibodies of the present invention include, but are not limited to, methods of detecting RGC-32 in a sample, methods of assaying cell proliferation, as well as methods of detecting and/or monitoring the progression of abnormal conditions in a subject, where the disease states are associated with the presence or absence of RGC-32. | 2011-02-10 |
20110034345 | METHODS FOR DIAGNOSIS OF MACULOPATHIES - The present disclosure provides methods for diagnosing a maculopathy. Specifically, the methods are based on determination of a level of at least one biological marker of a maculopathy in a bodily fluid sample of an individual (e.g. blood sample) and comparing the level of the assayed biological marker with the level of prior determined cut off standards. The level of the biological marker provides information regarding the state of the individual, such as whether the individual has the assayed maculopathy, is predisposed to develop said maculopathy, is responsive to treatment, and others. | 2011-02-10 |
20110034346 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 2011-02-10 |
20110034347 | Signatures Associated with Rejection or Recurrence of Cancer - Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols. | 2011-02-10 |
20110034348 | DEVICE FOR THE STUDY OF LIVING CELLS - A cell study device, comprising, a base layer, a planar conduit defining layer, including a conduit cut out of the layer; and a planar cover layer which defines a capillary flow channel in said conduit layer, said conduit layer and said cover layer acting as side walls for said capillary flow channel, wherein said layers are formed of materials that do not interfere with cell behavior over a period of at least 5 hours when loaded with aqueous solution. | 2011-02-10 |
20110034349 | siRNA targeting proto-oncogene MET - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET. | 2011-02-10 |
20110034350 | Protein Arrays and Methods of Use Thereof - The present invention provides human protein arrays that include at least 1000 human proteins. In another embodiment, the present invention provides a method for identifying a substrate of an enzyme, comprising contacting the enzyme with a positionally addressable array comprising at least 100 proteins immobilized on functionalized glass surface, and identifying a protein on the positionally addressable array that is bound and/or modified by the enzyme, wherein a binding or modifying of the protein by the enzyme indicates that the protein is a substrate for the enzyme. In additional embodiments, provided herein are methods for making an array of at least 1000 human proteins under non-denaturing conditions, including human proteins that are difficult to express and/or difficult to isolate in a non-denatured state. | 2011-02-10 |
20110034351 | Hydrophobically and Cationically Modified Relative Permeability Modifiers and Associated Methods - Methods and compositions including a method comprising introducing a hydrophobically and cationically modified relative permeability modifier into a portion of a subterranean formation, wherein the hydrophobically and cationically modified relative permeability modifier comprises a hydrophilic polymer backbone with a hydrophobic modification and a cationic modification. | 2011-02-10 |
20110034352 | RHEOLOGY MODIFIER FOR POLYMER FLUIDS - Embodiments of this invention relate to a composition and a method for tailoring the rheology of a fluid for use in the oil field services industry including forming a fluid comprising a tetrakis(hydroxyalkyl) phosphonium salt and a polymer, and exposing the fluid to a temperature of about 20° C. to about 200° C., wherein a viscosity is observed that is at least about 5 percent different than if no salt were present. Embodiments of this invention also relate to a composition and a method for tailoring the rheology of a fluid for use in the oil field services industry including forming a fluid comprising a tetrakis(hydroxyalkyl) phosphonium salt and diutan and/or guar and/or guar derivatives and/or a combination thereof, and exposing the fluid to a temperature of about 20° C. to about 163° C., wherein a viscosity is observed that is at least about 5 percent lower than if no salt were present. Embodiments of this invention also relate to a composition and a method for tailoring the rheology of a fluid for use in the oil field services industry including forming a fluid comprising a tetrakis(hydroxyalkyl) phosphonium salt and xanthan, and exposing the fluid to a temperature of about 20° C. to about 200° C., wherein a viscosity is observed that is at least about 5 percent higher than if no salt were present. | 2011-02-10 |
20110034353 | Method of Preparing a Nanoparticulate Iron - Crown Ether Complex - A stabilized nano-Fe | 2011-02-10 |
20110034354 | SLIDING BEARING - The invention relates to a sliding bearing ( | 2011-02-10 |
20110034355 | COMPOSITION COMPRISING PERFLUOROPOLYETHER - A composition is disclosed which comprises an aryl perfluoropolyether, optionally a halogenated oil, and further optionally a thickening agent. The composition can be used as a lubricant itself or as an additive to an oil or grease lubricant and can withstand temperatures higher than 300° C. without decomposition. The halogenated oil can be a perfluoropolyether, a fluorosilicone, a polytrifluorochloroethylene, or combinations of two or more thereof. The thickening agent can be finely divided silica, boron nitride, clay, soap, poly(tetrafluoroethylene), clay, talc, silica, titanium dioxide, polydimethylsiloxane, polyurea, polyurethane, or combinations of two or more thereof. | 2011-02-10 |
20110034356 | COMPOSITION COMPRISING PERFLUOROPOLYETHER - A composition is disclosed which comprises an aryl perfluoropolyether, optionally a halogenated oil, and further optionally a thickening agent. The composition can be used as a lubricant itself or as an additive to an oil or grease lubricant and can withstand temperatures higher than 300° C. without decomposition. The halogenated oil can be a perfluoropolyether, a fluorosilicone, a polytrifluorochloroethylene, or combinations of two or more thereof. The thickening agent can be finely divided silica, boron nitride, clay, soap, poly(tetrafluoroethylene), clay, talc, silica, titanium dioxide, polydimethylsiloxane, polyurea, polyurethane, or combinations of two or more thereof. | 2011-02-10 |
20110034357 | COMPOSITION AND METHOD FOR FORMING COATING FILM - To provide a novel composition useful as lubricant composition or the like. | 2011-02-10 |
20110034358 | LUBRICATING OIL COMPOSITION - The present invention provides a lubricating oil composition that is excellent in anti-fatigue properties for metals and load bearing properties while having improved fuel efficiency. The lubricating oil composition comprises (A) one type or a mixture of two or more types of mineral base oil having a 40° C. kinematic viscosity of from 5 to 15 mm | 2011-02-10 |
20110034359 | LUBRICANT COMPOSITION - A lubricant composition includes a base oil and one or more alkylethercarboxylic acid corrosion inhibitor(s) having the formula; | 2011-02-10 |
20110034360 | ALPHA-OLEFIN/ISOBUTENE DIBLOCK COPOLYMERS - The present invention relates to diblock copolymers of the formula A-B which are formed from a polymer block A which is formed essentially from α-olefin units having from 6 to 22 carbon atoms, and a polymer block B which is formed essentially from isobutene units, to a process for their preparation, to their use in lubricant compositions and to lubricant compositions which comprise such diblock copolymers. | 2011-02-10 |
20110034361 | CONCENTRATED BASE FOR DETERGENT PRODUCTS AND PRODUCTS FOR PERSONAL CARE AND HYGIENE COMPRISING A COMBINATION OF AT LEAST THREE NON-ETHOXYLATED SURFACTANTS - The invention relates to a concentrated base, particularly for detergent products and products for personal care and hygiene, comprising a combination of at least three surfactants selected from the group consisting of acylmethyltaurates, alkylamidopropylbetaines, alkyl amphoacetates, alkyl amphodiacetates, alkylsulphoacetates, acyl sarcosinates, acyl lactylates and acyl glutamates. The viscosity of the concentrated base of the invention can advantageously be adjusted by simple dilution with water to the concentration of use and/or by adding small amounts of electrolytes. Detergent products and products for personal care and hygiene comprising the concentrated base of the invention are also described. | 2011-02-10 |
20110034362 | Semi-Aqueous Stripping and Cleaning Formulation for Metal Substrate and Methods for Using Same - The present invention relates to semi-aqueous formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, as well as contaminations. The formulation comprises: an alkanolamine, a water miscible organic co-solvent, a quarternary ammonium compound, a non-free acid functionality corrosion inhibitor, and remainder water. The pH is greater than 9. | 2011-02-10 |
20110034363 | Specific Branched Surfactants and Consumer Products - A surfactant composition comprising one or more surfactant derivatives of isomers of acyclic detergent alcohol having 11, 16, or 21 carbon atoms and two, three, four or five methyl or ethyl branches or mixtures thereof wherein the surfactant derivatives are selected from the group consisting of cationic surfactants, zwitterionic surfactants, amine oxide surfactants, alkylpolyglycoside surfactants, soaps, fatty acids, di-long-chain alkyl cationic surfactants and mixtures | 2011-02-10 |
20110034364 | Color-Protecting Detergent or Cleanser - Improved color protection of detergents and cleansers used for washing or cleaning colored textile fabrics is provided with use of porous polyamide particles in the detergent or cleanser. | 2011-02-10 |
20110034365 | Laundry Detergent Composition Comprising a Highly Water-Soluble Carboxymethyl Cellulose Particle - A solid laundry detergent composition having: (a) detersive surfactant; and (b) from 0.05 wt % to 20 wt % carboxymethyl cellulose particle, wherein the carboxymethyl cellulose particle: (i) from 70 wt % to 98 wt % carboxymethyl cellulose having an average degree of carboxymethyl substitution of from 0.6 to 0.9; (ii) from 2 wt % to 12 wt % water; (iii) optionally from 0 wt % to 4 wt % sodium glycolate; and (iv) optionally from 0 wt % to 4 wt % sodium chloride. | 2011-02-10 |
20110034366 | LIQUID TREATMENT COMPOSITION - According to the present invention there is provided a pearlescent liquid treatment composition suitable for use as a laundry or hard surface cleaning composition comprising a rheology modifier providing a pouring viscosity at 20 sec | 2011-02-10 |
20110034367 | Liquid Enzyme Composition - Incorporation of a serine protease inhibitor such as RASI, BASI, WASI (bifunctional alpha-amylase/subtilisin inhibitors of rice, barley and wheat) into a liquid detergent which contains a serine proteasecan stabilize the serine protease and/or a second enzyme and can release the enzyme when the detergent composition is diluted. | 2011-02-10 |
20110034368 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. Where the polyprotein contains immunoglobulin heavy and light chain segments or fragments capable of antigen recognition, in an embodiment a selectable stoichiometric ratio is at least two copies of a light chain segment per heavy chain segment, with the result that the production of properly folded and assembled functional antibody is made. Modified signal peptides, including such from immunoglobulin light chains, are described. | 2011-02-10 |
20110034369 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the human bitter-taste receptor hTAS2R7 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R7 bitter taste transduction or bitter taste response. | 2011-02-10 |
20110034370 | BIS-MET HISTONES - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 2011-02-10 |
20110034371 | L. CASEI RHAMNOSUS SECRETED FACTORS AND USE THEREOF - The present invention relates to a composition for inhibiting gastrointestinal inflammation comprising an effective amount of | 2011-02-10 |
20110034372 | TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE - The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism. | 2011-02-10 |
20110034373 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention. | 2011-02-10 |
20110034374 | Oxyntomodulin for Preventing or Treating Excess Weight - Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake. | 2011-02-10 |
20110034375 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS - The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. | 2011-02-10 |
20110034376 | Use of Lipid-Rich Nutrition for the Treatment of Post-Operative Ileus - The invention pertains to the use of a lipid-rich nutrition for the manufacture of a composition for the prevention and/or treatment of post-operative ileus. The lipid fraction inhibited IL-6 and TNF-α levels in peritoneal lavage fluid, and/or wherein the lipid fraction prevents influx of neutrophils in the intestinal muscularis following intestinal manipulation. The nutritional composition comprises at least a lipid fraction which accounts for 42 to 90%, preferably between 45 and 70% of the total energy of the composition. The lipid fraction preferably contains 8 to 50 wt % of phospholipids. | 2011-02-10 |
20110034377 | Exendin and Exendin Agonists for Eating Disorders - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 2011-02-10 |
20110034378 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R | 2011-02-10 |
20110034379 | Gastrin Compositions And Formulations, And Methods Of Use And Preparation - An embodiment of the invention provided herein is a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided. | 2011-02-10 |
20110034380 | COMBINATION OF A SELECTIVE PPAR-GAMMA MODULATOR AND AN INCRETIN FOR THE TREATMENT OF DIABETES AND OBESITY - The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a selective PPARγ modulator and an incretin. The methods include the administration of the combination of a selective PPARγ modulator and an incretin. | 2011-02-10 |
20110034381 | Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH) - Therapeutic methods for treatment of benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I). Methods encompass the use of IGF-I antagonists, as well as the use of compounds that lower the effective level of IGF-I or interfere with post receptor effects of IGF-I action in the prostate. | 2011-02-10 |
20110034382 | USE OF LIVER GROWTH FACTOR (LGF) AS A NEURAL TISSUE REGENERATOR - The invention comprises the use of LGF in the production of medicinal products that can be used in the pleiotropic tissue regeneration of one or more damaged tissues, in which at least one of the damaged tissues forms part of the central nervous system and the medicinal product is intended to be administered systemically. The invention is based on the fact that intraperitoneal administration of LGF can promote a positive effect on a Parkinson's disease model. As such, in a preferred embodiment of the invention, the medicinal product is intended for the treatment of Parkinson's disease, particularly when the medicinal product is intended for humans. | 2011-02-10 |
20110034383 | CXCL12 GAMMA A CHEMOKINE AND USES THEREOF - Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans. | 2011-02-10 |
20110034384 | COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS - The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with mTOR inhibitors. The present disclosure also relates to methods of preventing the development of VEGFR2 resistance. | 2011-02-10 |
20110034385 | Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder - The present invention provides a supramolecular protein assembly useful as a protein therapeutics for the treatment of metabolic disorders particularly diabetes. The supramolecular protein assembly disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising supramolecular protein assembly. The composition disclosed in the present invention particularly comprises supramolecular insulin assembly. | 2011-02-10 |
20110034386 | DENDROASPIS NATRIURETIC PEPTIDE FOR TREATMENT OF CANCER - Disclosed is a method of inhibiting the growth of a cancer cell using | 2011-02-10 |
20110034387 | POLYPEPTIDE INHIBITING ANGIOGENESIS AND APPLICATION THEREOF - Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis. | 2011-02-10 |
20110034388 | COLLAGEN AND FIBRIN MICROTHREADS IN A DISCRETE THREAD MODEL OF IN VITRO ACL SCAFFOLD REGENERATION - Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues. | 2011-02-10 |
20110034389 | ACTIVE AGENTS, COMPOSITIONS, AND METHODS FOR INHIBITING AND REVERSING PLATELET FUNCTION - Active agents, compositions, and methods for inhibiting and reversing platelet function are provided herein. In particular embodiments, the active agents provided herein inhibit or reverse platelet function. In particular embodiments, the compositions described herein are pharmaceutical formulations. Methods of inhibiting and reversing platelet function are also provided herein. In particular embodiments, methods as described herein include administration of a Sema3E polypeptide. Further, methods of treating pathologic conditions associated with platelet function (i.e., platelet activation) and methods of screening active agent candidates are also provided. | 2011-02-10 |
20110034390 | PEPTIDES, COMPOSITIONS, AND USES THEREOF - Compositions for regenerating tissue and wound repair, among other applications, are described. | 2011-02-10 |
20110034391 | SHAPED ARTICLE - The shaped article is obtained via a cementitious reaction of a particulate composition reactive with water, whereby said reaction is obtained between said composition and an aqueous, liquid or gaseous phase. The particles of the shaped article are present in the form of interlocked particles, whereby the interlocking of said particles is obtained in a 100% water-saturated atmosphere. | 2011-02-10 |
20110034392 | Hyaluronic Acid and Chondroitin Sulfate Based Hydrolyzed Collagen Type II and Method of Making Same - Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual. | 2011-02-10 |
20110034393 | USE OF A NOVEL NATURAL AGENT IN COSMETIC COMPOSITIONS - The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods. | 2011-02-10 |
20110034394 | COMPOSITION COMPRISING PROTEIN AND DISPERSE FAT - The present invention relates to a method for the manufacture of a composition comprising proteins and fats, said method providing a simple and non-expensive way of obtaining fat-containing proteinaceous products of high nutritional value that are easy to handle and at the same time possess high stability towards coalescence and oxidation. More particularly, a method is provided for the manufacture of a composition comprising protein and fat in disperse form, the method comprising the following steps: (i) providing a suspension having a pH value higher than 7.0, said suspension comprising water, proteinaceous material, fat, and optionally alkali; (ii) incubating the suspension from (i) at a temperature in the interval 50-150° C.; (iii) homogenizing the suspension from (ii) to form a dispersion; and (iv), if desired, subjecting the dispersion from (iii) to a subsequent treatment; wherein the proteinaceous material in step (i) comprises vegetable-based proteinaceous material, and/or yeast-based proteinaceous material; wherein the suspension in step (i) comprises at least 5% fat by weight of dry matter. The current invention also relates to the compositions obtained by the method and to compositions obtainable by the method of the invention and, further, to the use of these compositions. | 2011-02-10 |
20110034395 | COMPOSITIONS AND METHODS OF INHIBITING APOPTOSIS - A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2. | 2011-02-10 |
20110034396 | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions - The present disclosure provides methods of use of saratin, including the prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Adhesion, keloid and/or scar formation may also be prevented in surgical procedures utilizing shunts, implants or drainage devices, including surgical procedures to treat glaucoma. | 2011-02-10 |
20110034397 | INTESTINAL IMMUNE SYSTEM STIMULATOR - Disclosed is an agent, γ-glutamylcysteine, which can effectively and safely stimulate the intestinal immune system. γ-Glutamylcysteine can be formulated in a pharmaceutical composition, a food, and/or a beverage, and used for the treatment or prevention of infectious diseases, diarrhea, polyps, tumors, enteritis or allergy. | 2011-02-10 |
20110034398 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 2011-02-10 |
20110034399 | Liquid and Freeze Dried Formulations - The present invention relates to stable parenteral formulations comprising a new class of compounds, which is a non proteinic compound, a method for preparing such formulations as well as the use of certain compounds for stabilizing these formulations. | 2011-02-10 |
20110034400 | COMPOSITIONS AND METHODS FOR ANALYZING BACTERIAL ADHERENCE AND ANTI-ADHERENCE TO MUCUS, EPITHELIAL CELLS AND OTHER CELLS - The present invention generally relates to methods for detecting, identifying, and measuring bacterial adherence to mucus and epithelial cells. In particular, the present invention provides assays for detecting and identifying the presence or absence of bacterial adherence to mucus (epithelial cells (e.g., present in the intestines), or other portion of an animal where bacteria may be present, and methods for identifying and characterizing (e.g., the efficacy of) modulators of bacterial adherence to mucus and epithelial cells, or other portion of the animal where bacteria may be present. | 2011-02-10 |
20110034401 | NOVEL PROCESS FOR SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 2011-02-10 |
20110034402 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY - This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, in particular for use thereof as a drug, notably in the treatment of diabetes. | 2011-02-10 |
20110034403 | USE OF GINSENOSIDE RG1, ITS METABOLITES GINSENOSIDE RH1 AND/OR PPT - The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient. | 2011-02-10 |
20110034404 | PEST CONTROL AGENTS - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier: | 2011-02-10 |
20110034405 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF - The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. | 2011-02-10 |
20110034406 | System And Method For Controlling Bacterial Persister Cells With Weak Electric Currents - A system and method for treating persister cells with an electrochemical process, alone or in combination with antibiotics. Weak electric currents are used to effectively eliminate persister cells and the efficacy can be further improved through synergistic effects with antibiotics. The method may be adapted for novel therapies of chronic infections and strategies to control persistent biofouling. The system has a broad spectrum applications in treating chronic and drug resistant infections, such as those caused by | 2011-02-10 |
20110034407 | USE OF SPHINGOMYELIN AND NON-DIGESTIBLE CARBOHYDRATES FOR IMPROVING INTESTINAL MICROBIOTA - A composition comprising sphingophospholipid or its degradation product and at least one non-digestible carbohydrate for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition. | 2011-02-10 |
20110034408 | HIGH OIL CONTENT O/W EMULSIONS STABILIZED WITH A HYDROPHOBICALLY MODIFIED INULIN AND A HYDROPHILIC ACRYLIC POLYMER - The invention relates to a composition in the form of an oil-in-water emulsion comprising, in a physiologically acceptable medium: i) at least 0.005% by weight, preferably at least 0.01% by weight, relative to the total weight of the composition, of at least one inulin modified with hydrophobic chains, and ii) at least 0.01% by weight, preferably at least 0.05% by weight, of active substance relative to the total weight of the composition, of at least one hydrophilic acrylic polymer selected from the at least partially neutralized, crosslinked acrylic homopolymers or copolymers, the polyacrylamidomethyl-propanesulphonic acid (AMPS) homopolymers and mixtures thereof. It also relates to a cosmetic method employing said composition. | 2011-02-10 |
20110034409 | USE OF PHARMACEUTICAL COMPOUND IN THE TREATMENT OF WOUNDS - A pharmaceutical composition that can be used in the treatment of wounds, comprising at least a sulfated polysaccharide and wherein the polysaccharide/s are in the form of solids as powder, flakes or sheets obtained through a lyophylization process. Particularly, this invention relates to the use of one or more sulfated polysaccharides, as solids in the form of sheets obtained by lyophylization, in the healing of wounds in humans and animals. | 2011-02-10 |
20110034410 | Wound dressing and method for controlling severe, life-threatening bleeding - This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer, a polyacrylic polymer or a combination thereof, The kind of severe, life-threatening bleeding contemplated by this invention is typically of the type not capable of being stanched when a conventional gauze wound dressing is applied with conventional 10 pressure to the subject wound. The wound dressing being capable of substantially stanching the flow of the severe life-threatening bleeding from the wound by adhering to the wound site, to seal the wound, to accelerate blood clot formation at the wound site, to reinforce clot formation at the wound site and prevent bleed out from the wound site, and to substantially prohibit the flow of 15 blood out of the wound site. | 2011-02-10 |
20110034411 | Methods and compositions for improving gastrointetinal health - Methods for maintaining or improving the gastrointestinal health of animals susceptible to or suffering from poor gastrointestinal health by administering to the animal a gastrointestinal health maintaining or improving amount of a food composition comprising from about 1 to about 20% carbohydrate; from about 3 to about 10% total dietary fiber, wherein the total dietary fiber contains from about 10 to about 40% soluble fiber and from about 90 to about 60% insoluble fiber; and from about 0.1 to about 10% omega-3 fatty acids; wherein the composition has a digestibility coefficient of at least 80. Generally, the compositions are administered to the animal to prevent or treat diarrhea or to improve stool quality. Further, the compositions may be administered in conjunction with one or more probiotics, prebiotics, anti-gastritis drugs, anti-enteritis drugs, or anti-diarrhea drugs, microbial exopolysaccharides, or combinations thereof to maintain or improve gastrointestinal health. | 2011-02-10 |
20110034412 | VISUALLY OBSERVABLE MATERIAL FOR MEDICAL TREATMENT - A visually observable material for medical treatment, which is preferable as an adhesion preventive material and a hemostatic material for biological organisms includes a crosslinking composition comprising at least two components of a crosslinking polysaccharide derivative with an active ester group reactive with active hydrogen in the co-presence of an alkali, where the active ester group is preliminarily introduced in a side chain of a polysaccharide and the crosslinking polysaccharide derivative is not yet crosslinked, and a carbonate including at least one type of carbonate generating divalent carbonate ion in an amount at a mass ratio of 0.03 or more to the polysaccharide derivative. | 2011-02-10 |
20110034413 | NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS - The present invention provides novel Quercetin derivatives of formula (I) and pharmaceutically acceptable salts, hydrates, and solvates thereof, | 2011-02-10 |
20110034414 | FLUOROALKYLOXY ALKANES, PROCESS FOR PRODUCTION AND USES THEREOF - The present invention relates to fluoroalkyloxy alkanes having formula (I): R | 2011-02-10 |
20110034415 | WALNUT EXTRACTS FOR NUTRACEUTICAL APPLICATIONS - The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined. | 2011-02-10 |
20110034416 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER - Disclosed are compounds of Formula (I): | 2011-02-10 |
20110034417 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE - Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors. | 2011-02-10 |
20110034418 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE - The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers, to poorly water-soluble salts of such bisphosphonates, to crystalline forms of the free compounds and the salts and to other related aspects, where the compounds are of the Formula (I), where R | 2011-02-10 |
20110034419 | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease - Disclosed are methods of diagnosing cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of predicting cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of identifying subjects at risk of developing cardiovascular disease comprising measuring sphingolipids. | 2011-02-10 |
20110034420 | NOVEL CRYSTALLINE FORM B OF (2R)-(3-AMINO-2-FLUOROPROPYL)PHOSPHINIC ACID - The present invention relates to a novel crystalline form of (2R)-(3-amino-2-fluoropropyl)phosphinic acid, the present invention is also directed to the use of the crystalline form for the treatment of gastrointestinal disorders as well as to a pharmaceutical compositions comprising the same and a process for the preparation of the crystalline form. | 2011-02-10 |
20110034421 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 2011-02-10 |